Patients were randomly assigned to receive oral paricalcitol or placebo. Dosing took place three times weekly, starting at 2 µ g or 4 µ g per dose (two trials) or once daily, starting at 1 µ g ...

This health-economic analysis investigated the cost, cost-effectiveness and cost-utility of intravenous paricalcitol compared with oral calcitriol and oral and intravenous alfacalcidol.

The prevalence of anemia (Hb <10g/dL) was 29% and hyperphosphatemia (P >5.5mg/dL), 30%. There was an increase in the frequency of use of cinacalcet and paricalcitol. The estimated overall crude annual ...

aCenter for Renal Translational Medicine/Institute for Metabolomic Medicine, University of California San Diego, San Diego, CA, United States bDepartment of Clinical and Molecular Medicine, Faculty of ...

Diabetes is a highly prevalent metabolic disease that has emerged as a global challenge due to its increasing prevalence and lack of sustainable treatment. Diabetic kidney disease (DKD), which is one ...